PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas, Texas.\', \'Eli Lilly and Company, Indianapolis, Indiana.\', \'Department of Medicine, Women\'s Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California.\', \'Vitalink Research, Union, South Carolina.\', \'Long Beach Clinical Trials, Long Beach, California.\', \'Imperial Health, Lake Charles, Louisiana.\', \'Cook County Health, Chicago, Illinois.\', \'Indago Research, Hialeah, Florida.\', \'Las Vegas Medical Research Center, Las Vegas, Nevada.\', \'Feinberg School of Medicine, Northwestern University, Chicago, Illinois.\', \'Franciscan Health, Greenwood, Indiana.\', \'Georgetown University, Washington, DC.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1001/jama.2021.0202
?:hasPublicationType
?:journal
  • JAMA
is ?:pmid of
?:pmid
?:pmid
  • 33475701
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33475701>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33475701>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all